FMP

FMP

Enter

SESN - Sesen Bio, Inc.

photo-url-https://financialmodelingprep.com/image-stock/SESN.png

Sesen Bio, Inc.

SESN

NASDAQ

Inactive Equity

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

0.629 USD

0.0427 (6.79%)

About

ceo

Dr. Thomas R. Cannell D.V.M.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-e...

CIK

0001485003

ISIN

US8177631053

CUSIP

817763105

Address

245 First Street

Phone

617 444 8550

Country

US

Employee

17

IPO Date

Feb 6, 2014

SESN Financial Summary

CIK

0001485003

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

817763105

ISIN

US8177631053

Country

US

Price

0.63

Beta

0.83

Volume Avg.

1.24M

Market Cap

127.96M

Shares

-

52-Week

0.365-0.965

DCF

1.52

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-6.29

P/B

-

Website

https://sesenbio.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest SESN News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep